POS1111 TREATMENT WITH UPADACITINIB RESULTS IN THE INHIBITION OF A BROAD RANGE OF POTENTIALLY PATHOGENIC PATHWAYS IN NR-AXSPA AND BDMARD-IR AS PATIENTS: PROTEOMIC ANALYSIS FROM THE SELECT-AXIS 2 PHASE 3 STUDIES

Abstract

BackgroundUpadacitinib (UPA) 15 mg QD, an oral Janus kinase inhibitor, demonstrated efficacy in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and patients with ankylosing spondylitis (AS) with an inadequate response (IR)...